About Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical Group Co., Ltd. is a pharmaceutical group specialising in new drug development, listed in Shenzhen (002653), with its registered domicile in Shannan, Tibet, and its main R&D and operating centre in Chengdu, Sichuan. It integrates research, production and commercialisation, with a portfolio centred on Class 1 innovative drugs under the Chinese new-drug classification.
Its flagship product is ciprofol (Sishuning), the first innovative intravenous anaesthetic with independent intellectual property rights developed in China, launched in 2020 for sedation and general anaesthesia. Other approved innovative drugs include crisugabalin capsules for neuropathic pain, cofrogliptin tablets for type 2 diabetes and enrecofen injection, alongside an established line of parenteral nutrition, digestive-hepatic and cardiovascular generics.
According to its official English website, the company has more than twenty Class 1 innovative drug projects in clinical development across anaesthesia and analgesia, respiratory diseases, chronic metabolic diseases, autoimmune diseases, oncology and digestive and hepatic diseases. Haisco regularly features in China's top 100 pharmaceutical innovation rankings and has out-licensed international rights to several of its candidates.
Its flagship product is ciprofol (Sishuning), the first innovative intravenous anaesthetic with independent intellectual property rights developed in China, launched in 2020 for sedation and general anaesthesia. Other approved innovative drugs include crisugabalin capsules for neuropathic pain, cofrogliptin tablets for type 2 diabetes and enrecofen injection, alongside an established line of parenteral nutrition, digestive-hepatic and cardiovascular generics.
According to its official English website, the company has more than twenty Class 1 innovative drug projects in clinical development across anaesthesia and analgesia, respiratory diseases, chronic metabolic diseases, autoimmune diseases, oncology and digestive and hepatic diseases. Haisco regularly features in China's top 100 pharmaceutical innovation rankings and has out-licensed international rights to several of its candidates.